(Q39452735)

12 September 2017

1 reference

title

Controlling cardiac arrhythmias: an overview with a historical perspective (English)

1 reference

12 September 2017

B N Singh

1

1 reference

12 September 2017

language of work or name

English

0 references

publication date

1 October 1997

1 reference

American Journal of Cardiology

12 September 2017

published in

1 reference

12 September 2017

volume

80

1 reference

12 September 2017

issue

8A

1 reference

12 September 2017

page(s)

4G-15G

1 reference

Long-term follow-up of asymptomatic healthy subjects with frequent and complex ventricular ectopy

12 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900709-1

The high risk patient after recovery from myocardial infarction: recognition and management

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900709-1

Ablation therapy for cardiac arrhythmias

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900709-1

Congenital deaf-mutism, functional heart disease with prolongation of the Q-T interval and sudden death

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900709-1

QUINIDINE SYNCOPE. PAROXYSMAL VENTRICULAR FIBRILLATION OCCURRING DURING TREATMENT OF CHRONIC ATRIAL ARRHYTHMIAS.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900709-1

A third class of anti-arrhythmic action. Effects on atrial and ventricular intracellular potentials, and other pharmacological actions on cardiac muscle, of MJ 1999 and AH 3474

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900709-1

The effect of amiodarone, a new anti-anginal drug, on cardiac muscle

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900709-1

Effect of Altering Potassium Concentration on the Action of Lidocaine and Diphenylhydantoin on Rabbit Atrial and Ventricular Muscle

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900709-1

Comparative mechanisms of action of antiarrhythmic drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900709-1

The Sicilian gambit. A new approach to the classification of antiarrhythmic drugs based on their actions on arrhythmogenic mechanisms. Task Force of the Working Group on Arrhythmias of the European Society of Cardiology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900709-1

The coming of age of the class III antiarrhythmic principle: retrospective and future trends

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900709-1

Arrhythmia control by prolonging repolarization: the concept and its potential therapeutic impact

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900709-1

Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900709-1

An antiarrhythmic drug experience in 941 patients resuscitated from an initial cardiac arrest between 1970 and 1985

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900709-1

Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900709-1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900709-1

A comparison of seven antiarrhythmic drugs in patients with ventricular tachyarrhythmias. Electrophysiologic Study versus Electrocardiographic Monitoring Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900709-1

A comparison of electrophysiologic testing with Holter monitoring to predict antiarrhythmic-drug efficacy for ventricular tachyarrhythmias. Electrophysiologic Study versus Electrocardiographic Monitoring Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900709-1

Randomized antiarrhythmic drug therapy in survivors of cardiac arrest (the CASCADE Study). The CASCADE Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900709-1

Randomized study of implantable defibrillator as first-choice therapy versus conventional strategy in postinfarct sudden death survivors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900709-1

Expanding indications for the use of Class III agents in patients at high risk for sudden death

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900709-1

Controlled trial of sotalol for one year after myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900709-1

Amiodarone-associated proarrhythmic effects. A review with special reference to torsade de pointes tachycardia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900709-1

Choice and chance in drug therapy of cardiac arrhythmias: technique versus drug-specific responses in evaluation of efficacy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900709-1

Double-blind trial of lignocaine versus sotalol for acute termination of spontaneous sustained ventricular tachycardia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900709-1

Sotalol versus quinidine for the maintenance of sinus rhythm after direct current conversion of atrial fibrillation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900709-1

Pharmacologic conversion and suppression of experimental canine atrial flutter: differing effects of d-sotalol, quinidine, and lidocaine and significance of changes in refractoriness and conduction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900709-1

Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation. Ibutilide Repeat Dose Study Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900709-1

Intravenous dofetilide, a class III antiarrhythmic agent, for the termination of sustained atrial fibrillation or flutter. Intravenous Dofetilide Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900709-1

Control of cardiac arrhythmias by selective lengthening of repolarization: theoretic considerations and clinical observations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900709-1

Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival With Oral d-Sotalol.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900709-1

Chronic amiodarone reduces transmural dispersion of repolarization in the canine heart

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900709-1

Effects of amiodarone, sematilide, and sotalol on QT dispersion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900709-1

Frequency-dependent electrophysiologic effects of amiodarone in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900709-1

Barium-induced nondriven action potentials as a model of triggered potentials from early afterdepolarizations: significance of slow channel activity and differing effects of quinidine and amiodarone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900709-1

Randomized, double-blind comparison of intravenous amiodarone and bretylium in the treatment of patients with recurrent, hemodynamically destabilizing ventricular tachycardia or fibrillation. The Intravenous Amiodarone Multicenter Investigators Grou

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900709-1

Dose-ranging study of intravenous amiodarone in patients with life-threatening ventricular tachyarrhythmias. The Intravenous Amiodarone Multicenter Investigators Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900709-1

Therapy of Sustained Ventricular Arrhythmias With Amiodarone: Prediction of Efficacy With Serial Electrophysiologic Studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900709-1

Adjunctive drug therapy of acute myocardial infarction--evidence from clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900709-1

Beta blockade during and after myocardial infarction: an overview of the randomized trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900709-1

Effect of propranolol after acute myocardial infarction in patients with congestive heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900709-1

Advantages of beta blockers versus antiarrhythmic agents and calcium antagonists in secondary prevention after myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900709-1

Amiodarone and post-MI patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900709-1

Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. European Myocardial Infarct Amiodarone Trial Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900709-1

Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900709-1

The effect of digoxin on mortality and morbidity in patients with heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900709-1

Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900709-1

Randomised trial of low-dose amiodarone in severe congestive heart failure. Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina (GESICA)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900709-1

Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900709-1

Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. The PRECISE Trial. Prospective Randomized Evaluation of Carvedilol on Symptoms and Exercise.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900709-1

Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. US Carvedilol Heart Failure Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900709-1

Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900709-1

Drugs versus devices in controlling ventricular tachycardia, ventricular fibrillation, and recurrent cardiac arrest

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900709-1

Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900709-1

Reflections on Recent Clinical Trials in Patients With Heart Failure and Those With Reduced Ventricular Function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900709-1

Amiodarone: the expanding antiarrhythmic role and how to follow a patient on chronic therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900709-1

10.1016/S0002-9149(97)00709-1

7 January 2021

Identifiers

DOI

1 reference

12 September 2017

1 reference